PASG

Analyst Ratings on Healthcare Stocks: Analysts have expressed bullish sentiments on Ventyx Biosciences, Black Diamond Therapeutics, and Passage Bio, with Ventyx receiving a Strong Buy consensus and significant upside potential from its current price.

Price Targets and Performance: Ventyx has a price target of $14.00, Black Diamond is rated with a Moderate Buy, and Passage Bio has a target of $13.00, indicating optimism despite their shares being close to 52-week lows.

Real-time Intelligence: Benzinga Pro offers traders the fastest news alerts and exclusive stories to enhance their market strategies.

Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from accurate stock market intelligence.

Clinical Trial Progress: Interim data from the PBFT02 clinical trial shows promising results in increasing cerebrospinal fluid progranulin levels and reducing plasma neurofilament light chain levels in FTD-GRN patients, with plans to report further data in 2025 and seek regulatory feedback in 2026.

Financial Overview: Passage Bio reported a net loss of $64.8 million for 2024 but extended its cash runway into Q1 2027 by implementing cost-reduction measures, while continuing to focus on advancing its gene therapy programs for neurodegenerative diseases.

Upcoming Investor Conferences: Passage Bio, Inc. will participate in the TD Cowen 45th Annual Health Care Conference on March 5, 2025, and the Leerink Global Biopharma Conference on March 12, 2025, with live webcasts available on their website.

Company Focus: Passage Bio is dedicated to developing genetic medicines for neurodegenerative diseases, with its lead product candidate, PBFT02, aimed at treating conditions like frontotemporal dementia by restoring lysosomal function.

Clinical Trial Updates: Passage Bio's PBFT02 shows promising results in increasing CSF PGRN levels and reducing plasma NfL levels in frontotemporal dementia patients, with plans to report further data in 2025 and seek regulatory feedback in 2026.

Operational Changes: The company has transitioned to an outsourced analytical testing model and reduced operating expenses, extending its cash runway into early 2027 while continuing to advance its clinical trials for FTD-GRN and FTD-C9orf72.

Fastest News Alerts: Benzinga Pro offers real-time intelligence and alerts to help traders stay informed and make winning trades in the stock market.

Exclusive Community: Joining Benzinga Pro connects you with over 10,000 serious traders and provides access to exclusive stories and accurate market intelligence.

Fastest News Alerts: Benzinga Pro offers real-time intelligence and news alerts to help traders stay informed and make winning trades in the stock market.

Community of Traders: The platform boasts a community of over 10,000 serious traders who benefit from exclusive stories and accurate market intelligence provided by Benzinga reporters.

Clinical Trial Progress: Passage Bio has enrolled 4 patients in Cohort 2 of the upliFT-D trial for FTD-GRN, with patient dosing on track and data from both cohorts expected in the first half of 2025. Interim results show PBFT02 is well-tolerated and effectively raises CSF progranulin levels.

Financial Overview: The company reported a net loss of $19.3 million for Q3 2024, down from $27.1 million in Q3 2023, with cash reserves expected to fund operations until the end of Q2 2026, indicating a strong financial position to support ongoing research and development efforts.

Company Presentation Announcement: Passage Bio, Inc. will have its CEO Will Chou present at Chardan's 8th Annual Genetic Medicines Conference on October 1, 2024, with a live webcast available for viewers.

Focus on Neurodegenerative Diseases: Passage Bio is dedicated to developing one-time genetic therapies aimed at treating neurodegenerative diseases, particularly through their lead product candidate, PBFT02, which targets frontotemporal dementia.

Interim Results from upliFT-D Trial: The upliFT-D trial for PBFT02 in patients with frontotemporal dementia (FTD) showed that Dose 1 significantly increased CSF progranulin levels, which were maintained for up to 12 months, and was well-tolerated among participants with no serious adverse events reported.

Upcoming Presentation: Passage Bio will present updated safety and biomarker data from the trial at ISFTD2024 on September 20, 2024, highlighting the potential of PBFT02 as a leading therapy for neurodegenerative diseases.

Appointment Announcement: Passage Bio, Inc. has appointed Tom Kassberg to its Board of Directors and Audit Committee; he brings extensive experience from Ultragenyx and other biotech firms to help advance the company's mission in neurodegenerative disease treatments.

Company Focus: Passage Bio is dedicated to developing innovative genetic therapies for neurodegenerative diseases, with its lead candidate PBFT02 aimed at treating conditions like frontotemporal dementia by enhancing progranulin levels.

Earnings Report: Passage Bio (NASDAQ:PASG) reported a second quarter 2024 earnings per share of -26 cents, surpassing the analyst estimate of -31 cents, but did not generate any revenue for the quarter.

Automated Coverage: InvestorPlace Earnings utilizes automated data analysis to quickly publish key financial figures and comparisons with analyst estimates, ensuring timely updates for readers.

Upcoming Investor Conferences: Passage Bio, Inc. will participate in the Canaccord Genuity 44th Annual Growth Conference on August 13, 2024, and the 15th Annual Wedbush PacGrow Healthcare Conference on August 14, 2024, with presentations and investor meetings scheduled.

Company Focus: Passage Bio is dedicated to developing genetic therapies for neurodegenerative diseases, particularly through its lead product candidate PBFT02, aimed at treating conditions like frontotemporal dementia by restoring lysosomal function.

Licensing Agreement: Passage Bio has granted GEMMA Biotherapeutics exclusive rights to develop and commercialize three of its clinical-stage programs for pediatric lysosomal storage diseases, with potential payments totaling up to $134 million.

Strategic Collaboration: The companies have entered a research collaboration agreement to advance genetic medicines for CNS conditions, including Huntington's disease, while extending Passage Bio's cash runway to the end of Q2 2026.